Monopar Therapeutics (MNPR) Total Liabilities (2016 - 2020)
Historic Total Liabilities for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $664468.0.
- Monopar Therapeutics' Total Liabilities rose 3738.16% to $664468.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $664468.0, marking a year-over-year increase of 3738.16%. This contributed to the annual value of $724165.0 for FY2019, which is 8124.47% up from last year.
- Latest data reveals that Monopar Therapeutics reported Total Liabilities of $664468.0 as of Q3 2020, which was up 3738.16% from $648148.0 recorded in Q2 2020.
- Monopar Therapeutics' Total Liabilities' 5-year high stood at $724165.0 during Q4 2019, with a 5-year trough of $64510.0 in Q4 2016.
- In the last 5 years, Monopar Therapeutics' Total Liabilities had a median value of $443520.0 in 2020 and averaged $439515.8.
- Per our database at Business Quant, Monopar Therapeutics' Total Liabilities skyrocketed by 38343.98% in 2017 and then tumbled by 2352.92% in 2020.
- Quarter analysis of 5 years shows Monopar Therapeutics' Total Liabilities stood at $64510.0 in 2016, then skyrocketed by 383.44% to $311867.0 in 2017, then grew by 28.12% to $399551.0 in 2018, then surged by 81.24% to $724165.0 in 2019, then decreased by 8.24% to $664468.0 in 2020.
- Its Total Liabilities was $664468.0 in Q3 2020, compared to $648148.0 in Q2 2020 and $443520.0 in Q1 2020.